Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediat...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2023
|
| In: |
The journal of clinical investigation
Year: 2023, Volume: 133, Issue: 13, Pages: 1-12 |
| ISSN: | 1558-8238 |
| DOI: | 10.1172/JCI170762 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1172/JCI170762 Verlag, kostenfrei, Volltext: https://www.jci.org/articles/view/170762 
|
| Author Notes: | Feyza Gul Ozbay Kurt, Samantha Lasser, Ihor Arkhypov, Jochen Utikal, and Viktor Umansky |
| Summary: | Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediated by T and natural killer cells and promote tumor growth. They are major contributors to ICI resistance and play a crucial role in creating an immunosuppressive tumor microenvironment. Therefore, targeting MDSCs is considered a promising strategy to improve the therapeutic efficacy of ICIs. This Review describes the mechanism of MDSC-mediated immune suppression, preclinical and clinical studies on MDSC targeting, and potential strategies for inhibiting MDSC functions to improve melanoma immunotherapy. |
|---|---|
| Item Description: | Veröffentlicht: 3. Juli 2023 Gesehen am 28.09.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1558-8238 |
| DOI: | 10.1172/JCI170762 |